GLP-1 for osteoarthritis/knee pain

Knee osteoarthritis and obesity travel together. Every extra pound of body weight adds roughly four pounds of force across the knee with each step, so it is no surprise that losing weight has long been one of the few things that reliably eases knee pain. GLP-1 drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) drive large, sustained weight loss, which raises an obvious question: can they help arthritic knees too? The short answer in 2026 is that one strong trial says yes for people with obesity, one earlier trial said no, and the laboratory science is interesting but not yet proven in humans. This page walks through exactly what the data show, where the evidence is thin, and who might reasonably consider these drugs for joint pain.

How GLP-1 Drugs Might Help an Arthritic Knee

There are two separate theories for why a GLP-1 drug could ease osteoarthritis (OA) pain. They matter because they predict very different things, and the human evidence so far only supports one of them clearly.

Pathway one: weight loss takes load off the joint

This is the boring, well-established mechanism. Osteoarthritis of the knee is a mechanical disease as much as a biological one. The cartilage that cushions the joint wears down, bone rubs against bone, and the surrounding tissue becomes inflamed. Carrying more body weight increases the mechanical stress on the joint and also raises levels of inflammatory signals that fat tissue produces. Decades of research show that losing weight reduces knee pain and improves how well the joint works, in a clear dose-response pattern: more weight lost, more pain relief.

GLP-1 receptor agonists are, first and foremost, powerful weight-loss drugs. They slow stomach emptying, reduce appetite, and act on brain centers that control hunger. In obesity trials, semaglutide drives roughly 15% body weight loss and tirzepatide drives 20% or more. If even part of that translates to the knee, you would expect real pain relief simply from the unloading.

Pathway two: a direct effect on joint tissue

This is the more exciting and far less proven idea. GLP-1 receptors are not only in the gut and brain. Laboratory studies have found them in cartilage cells (chondrocytes) and in the synovium, the lining of the joint. Some preclinical work suggests that degenerated cartilage shows lower GLP-1 receptor activity than healthy cartilage, and that switching the receptor back on with a GLP-1 drug calms inflammation locally.

In animal and cell studies, liraglutide (an older GLP-1 drug) reduced inflammatory signals such as IL-6, prostaglandin E2, and nitric oxide in chondrocytes and joint macrophages, and shifted those immune cells from a pro-inflammatory state toward a repair state. In a mouse model of OA, a single injection of liraglutide into the joint reduced pain behavior within days. That is a direct, weight-independent effect, at least in mice.

Here is the honest caveat. None of this has been demonstrated in human joints. The 2025 systematic review of GLP-1 drugs in osteoarthritis found that no human study has actually measured the immune-modulating effect inside a person's knee. The "direct cartilage protection" story is a hypothesis built on rodents and petri dishes. Treat it as promising, not proven.

The Human Evidence, Study by Study

This is where claims get sorted from hype. Two randomized controlled trials have tested a GLP-1 drug specifically for knee osteoarthritis pain, and they reached opposite conclusions. That contradiction is the single most important thing to understand.

Trial	Drug	Design	Population	Pain result	Verdict
STEP 9 (2024)	Semaglutide 2.4 mg/week	68 wk, randomized, placebo-controlled, 407 people	Obesity (BMI ≥30) + moderate knee OA	WOMAC pain change −41.7 vs −27.5 with placebo (greater relief)	Positive
LOSEIT (2021)	Liraglutide 3 mg/day	52 wk after an 8-wk diet, randomized, placebo-controlled, ~156 people	Overweight/obese (BMI ≥27) + knee OA, already lost ≥5% weight	KOOS pain change +0.4 vs −0.6 with placebo (no difference)	Negative

STEP 9: the positive trial

STEP 9 is the headline study and the reason this topic exists. Published in the New England Journal of Medicine in October 2024, it was a 68-week, double-blind, placebo-controlled trial run at 61 sites in 11 countries. Researchers enrolled 407 adults with obesity (average BMI 40.3) and a clinical and X-ray diagnosis of moderate knee osteoarthritis. The average starting WOMAC pain score was 70.9 on a 0–100 scale, where higher means worse. Participants were assigned 2-to-1 to weekly semaglutide 2.4 mg or placebo, both on top of diet and exercise counseling.

The results were strong on both primary endpoints. Body weight fell 13.7% with semaglutide versus 3.2% with placebo. WOMAC pain improved by 41.7 points with semaglutide versus 27.5 points with placebo, a difference of about 14 points that was statistically significant. Physical function also improved more in the semaglutide group (a gain of about 12 points versus 6.5). Both groups improved, which underlines how much diet, exercise, and attention alone can help, but the drug clearly added benefit.

One detail is worth flagging carefully because it gets exaggerated. Commentators have claimed the pain relief in STEP 9 was "more than weight loss alone would predict." STEP 9 was not designed to separate the direct-joint effect from the weight-loss effect, and the placebo group lost relatively little weight. So while the size of the pain improvement is real and meaningful, the trial cannot prove a special weight-independent mechanism. Anyone telling you STEP 9 proves semaglutide protects cartilage is reading more into it than the data support.

It is also worth naming the funding. STEP 9 was sponsored by Novo Nordisk, the maker of semaglutide. Industry funding does not make a trial wrong, and NEJM peer review is rigorous, but it belongs in any honest summary. Independent replication would strengthen the case.

LOSEIT: the negative trial that gets forgotten

Three years before STEP 9, a different design produced a different answer. The LOSEIT trial, published in the American Journal of Clinical Nutrition in 2021, tested liraglutide 3 mg daily in people with knee OA. The twist: every participant first went through an 8-week strict diet and lost at least 5% of their weight before being randomized to the drug or placebo. The question was whether adding liraglutide on top of an already-achieved weight loss would further reduce pain.

It did not. Over 52 weeks, the liraglutide group kept slightly more weight off, but knee pain measured by the KOOS scale was essentially identical between groups (a change of +0.4 versus −0.6, a non-significant difference). In plain terms: once people had already lost weight by dieting, the GLP-1 drug added no extra pain relief.

Why do the two trials disagree? Probably because of what they tested. LOSEIT layered the drug on top of weight loss that had already happened, so most of the achievable pain benefit had been captured before the drug started. STEP 9 used a much more potent drug (semaglutide drives more weight loss than liraglutide) in people who had not yet lost weight, so the drug delivered both the weight loss and the pain relief that came with it. The simplest reading of both trials together is that GLP-1 drugs help arthritic knees mainly by driving weight loss, not through a separate magic effect on cartilage.

Observational signals: surgery and progression

Beyond the two randomized trials, larger but weaker observational data hint at longer-term benefit. A cohort study using a global health-records network reported that adults with knee OA who took GLP-1 drugs had a lower rate of total knee replacement over follow-up than non-users. The reported absolute risk reduction was modest, around 2.8 percentage points at eight years with one year of use of any GLP-1 drug, and somewhat larger with longer use of newer agents like semaglutide or tirzepatide.

Take this with real caution. Observational studies cannot prove cause and effect. People prescribed these drugs differ from those who are not in ways records cannot fully capture, and the authors themselves noted the effect was mostly explained by weight loss. The 2025 systematic review reached the same conclusion: the single cohort showing fewer knee surgeries was "mainly mediated by weight reduction." It is a supportive signal, not proof that the drugs slow the disease.

Putting the Pain Numbers in Context

How big is a 14-point WOMAC difference, really? On a 0–100 pain scale, a change most patients can feel is usually around 10 points or more. So the extra benefit from semaglutide in STEP 9 sits right around the threshold of being personally noticeable, on top of substantial improvement that both groups got. This is meaningful but not miraculous.

The weight-loss-to-pain relationship from earlier research helps anchor expectations:

Weight lost	Typical effect on knee OA
Under 5%	Little reliable change in pain or function
5% to 10%	Measurable improvement in pain and function
10% to 20%	Greater pain relief and substantially better function
Over 20%	Continued gains in function and quality of life, with further pain reduction

This dose-response pattern, drawn from long-term weight-loss trials in knee OA, is the real engine behind GLP-1 benefits. Semaglutide and especially tirzepatide can push patients into the 10–20%+ zone where the knee data are most favorable. That is the plausible, evidence-based reason to expect joint benefit, and it sets a fair expectation: the more weight comes off and stays off, the better the knee tends to feel.

For more on the magnitude of weight loss to expect, see our GLP-1 results timeline week by week and the broader GLP-1 by subgroup evidence review.

How GLP-1 Compares to Standard Osteoarthritis Care

GLP-1 drugs are not a first-line OA treatment, and no guideline currently recommends them for joint pain. They sit alongside, not in place of, the established core treatments.

Approach	What it does for knee OA	Evidence strength	Notes
Exercise and physical therapy	Strengthens muscles, improves function, reduces pain	Strong; guideline-recommended for everyone	Free or low cost; benefit is real but requires effort
Weight loss (any method)	Unloads the joint, lowers inflammation	Strong; guideline-recommended if overweight	The mechanism GLP-1 drugs work through
GLP-1 drugs (semaglutide, tirzepatide)	Drive large weight loss; one positive RCT for pain	Moderate and emerging; one positive trial, one negative	Not OA-approved; expensive; for people with obesity
NSAIDs (ibuprofen, naproxen)	Reduce pain and inflammation directly	Strong for short-term symptom relief	Stomach, kidney, and heart risks with long use
Corticosteroid injections	Short-term pain relief	Moderate; effect fades in weeks to months	Repeated use may harm cartilage
Knee replacement surgery	Definitive treatment for end-stage OA	Strong for severe, refractory disease	Major surgery; reserved for advanced cases

The 2019 American College of Rheumatology guideline strongly recommends exercise and, for people who are overweight, weight loss as core treatments for knee OA. GLP-1 drugs are best understood as a new, potent tool to achieve that recommended weight loss in people who also have obesity, not as a standalone arthritis drug. If you can achieve the same weight loss through diet and exercise, the LOSEIT trial suggests you may not need the drug for the joint benefit specifically.

For how these drugs stack up against each other on weight loss, see our semaglutide vs tirzepatide head-to-head comparison.

Safety: What to Weigh Before Starting

GLP-1 drugs are generally well tolerated, but they are not risk-free, and the side effects matter more when the goal is joint pain rather than a life-threatening condition.

The most common problems are gastrointestinal: nausea, vomiting, diarrhea, and constipation, usually worst when starting or increasing the dose. In the OA trials, GI complaints were the leading reason people stopped the drug. Slow dose increases and dietary adjustments reduce these effects for most people.

More serious but rarer concerns include pancreatitis, gallbladder disease (more likely with rapid weight loss), and a boxed warning on the FDA label for thyroid C-cell tumors based on rodent studies, which means these drugs are not for people with a personal or family history of medullary thyroid cancer or MEN 2 syndrome. The FDA-approved labeling for semaglutide for weight management spells out these warnings in detail.

There is also a joint-specific consideration. Rapid weight loss can cause loss of muscle along with fat, and strong muscles around the knee help protect and stabilize an arthritic joint. Losing muscle while losing weight could partly offset the benefit to the knee. This is why pairing a GLP-1 drug with resistance exercise and adequate protein matters. Our guides on preventing muscle loss on GLP-1 medications and managing GLP-1 side effects cover the practical steps.

Who Might Reasonably Consider a GLP-1 Drug for Knee OA

Based on the current evidence, the strongest case is for a specific person, not for anyone with knee pain.

A GLP-1 drug makes the most sense for someone who has both obesity (BMI 30 or higher) and symptomatic knee osteoarthritis, who has not yet lost meaningful weight, and who has struggled to do so through diet and exercise alone. That profile matches the STEP 9 population, where the benefit was demonstrated. For these patients, the drug offers a documented path to the weight loss that guidelines already recommend, plus the joint relief that tends to follow.

The case is much weaker for others. If you are at a normal weight with knee OA, there is no evidence GLP-1 drugs will help your joint, and the rodent "direct cartilage" theory is not nearly enough to justify the cost or risk. If you have already lost weight through other means, the LOSEIT trial suggests adding a GLP-1 drug may do nothing extra for the knee. And no one should expect these drugs to regrow cartilage or reverse established arthritis; that has not been shown in humans.

Cost and access are real barriers too. These drugs are expensive, often poorly covered by insurance when the indication is weight or joint pain rather than diabetes, and require ongoing use to maintain weight loss. Our GLP-1 cost and access guide breaks down the pricing landscape.

The Bottom Line

The evidence in 2026 supports a measured, honest conclusion. One strong randomized trial (STEP 9) shows that weekly semaglutide reduces knee osteoarthritis pain in people with obesity, and most of that benefit is best explained by the substantial weight loss the drug produces. An earlier trial (LOSEIT) found no extra pain benefit when a weaker GLP-1 drug was added after weight loss had already been achieved. The idea that GLP-1 drugs directly protect or repair cartilage is biologically interesting but rests on animal studies and has not been proven in human joints. No guideline currently recommends these drugs for arthritis, and they are not a substitute for exercise. For the right patient, someone with obesity and an aching knee who needs help losing weight, they are a reasonable, evidence-backed option. For everyone else, the case is not yet there.

Frequently Asked Questions

Does semaglutide reduce knee osteoarthritis pain?

Yes, in one strong trial. The STEP 9 trial found that weekly semaglutide 2.4 mg reduced knee OA pain significantly more than placebo in people with obesity over 68 weeks, alongside about 14% body weight loss. The pain relief is real, but it appears driven mainly by the weight loss rather than a separate effect on the joint.

Do GLP-1 drugs repair or regrow cartilage?

There is no human evidence that they do. Laboratory and animal studies suggest GLP-1 drugs can calm joint inflammation and protect cartilage cells, but these findings have not been confirmed in people. Do not expect a GLP-1 drug to reverse established arthritis or rebuild lost cartilage.

Is a GLP-1 drug approved for osteoarthritis?

No. As of 2026, no GLP-1 drug is FDA-approved to treat osteoarthritis or joint pain. Semaglutide and tirzepatide are approved for weight management and diabetes. Any use for knee OA would be off-label and would rely on the weight-loss benefit.

Will GLP-1 drugs help my knee if I am not overweight?

Probably not, based on current evidence. Every randomized trial tested these drugs in people who were overweight or obese, where the benefit comes from unloading the joint through weight loss. There is no good evidence they help arthritic knees in people at a normal weight.

Can a GLP-1 drug help me avoid knee replacement surgery?

Possibly, but this is unproven. One observational study linked GLP-1 use to a modestly lower rate of knee replacement over years, mostly explained by weight loss. Because it was not a randomized trial, it cannot prove the drug prevents surgery. It is an encouraging signal, not a guarantee.

References

Bliddal H, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (STEP 9). New England Journal of Medicine, 2024. The pivotal positive randomized trial.
Gudbergsen H, et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial (LOSEIT). American Journal of Clinical Nutrition, 2021. The negative trial showing no added pain benefit after weight loss.
Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: a systematic review of pre-clinical and human studies. Osteoarthritis and Cartilage Open, 2025. Summary of how thin the human evidence remains.
Meurot C, et al. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Scientific Reports, 2022. Key preclinical (animal/cell) mechanism study.
Messier SP, et al. Intentional Weight Loss in Overweight and Obese Patients With Knee Osteoarthritis: Is More Better? Arthritis Care & Research, 2018. Dose-response of weight loss on knee OA.
Riddle DL, Stratford PW. Body weight changes and corresponding changes in pain and function in knee osteoarthritis: a cohort study. Arthritis Care & Research, 2013. Evidence that ~10% weight loss is a meaningful threshold.
American College of Rheumatology. 2019 ACR/AF Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Core treatments: exercise and weight loss.
U.S. FDA. Wegovy (semaglutide) Prescribing Information, 2024. Boxed warning and full safety labeling.
PubMed search: GLP-1 receptor agonist knee osteoarthritis and semaglutide knee osteoarthritis pain. Ongoing literature.

This article is for general information only and is not medical advice. Talk to your doctor or pharmacist before starting, stopping, or changing any medication.